This page is an English translation of the Korean original. If there is any discrepancy, the Korean version prevails.
| Item | Details |
|---|---|
| A. Classification codes | ICD-10: L12.3 | Special Copayment Reduction: V176 (rare disease) |
| B. Synonyms | — |
| C. Adult onset | Likelihood of first presentation in adulthood: high — acquired epidermolysis bullosa can occur at any age but is mainly diagnosed in adults, and onset in early to middle adulthood is common, especially when it accompanies inflammatory bowel disease (Crohn's disease). |
| 1. History | Acquired epidermolysis bullosa (Acquired Epidermolysis Bullosa, AEB or EBA) is a dermal-epidermal junction… |
| 2. Causes | Acquired epidermolysis bullosa … the basement membrane component protein located at the dermal-epidermal junction (DEJ), type VII collagen (type… |
| 3. Genetics | Acquired epidermolysis bullosa is a complex genetic disease. HLA-DR2 (HLA-DRB1*15:01) is the strongest genetic risk factor… |
| 4. General epidemiology | Acquired epidermolysis bullosa is a very rare disease among autoimmune blistering diseases, with an annual incidence of 0.5~2 per 1 million population… |
| 5. Pathophysiology | The pathophysiology of acquired epidermolysis bullosa is damage to anchoring fibrils and sub-basement membrane cleavage caused by anti-COL7A1 IgG autoantibodies.… |
| 6. Symptoms | The clinical symptoms of acquired epidermolysis bullosa are broadly divided into the classic and inflammatory types. Classic (non-inflammatory) type |
| 7. Signs | The physical signs of classic AEB are recurrent blisters, scars, milia, and dystrophic nail changes on the extensor surfaces. Skin fragility is evident, so… |
| 8. Screening | Screening tests for acquired epidermolysis bullosa are performed in patients who do not respond to treatment for other autoimmune blistering diseases, and in patients with recurrent blisters and scars on the extensor surfaces… |
| 9. Diagnosis | Confirmation of acquired epidermolysis bullosa is made by integrating clinical findings, histopathology, DIF, IIF, and ELISA. On histopathology, the basal… |
| 10. Treatment | Acquired epidermolysis bullosa is more treatment-resistant than other autoimmune blistering diseases. As first-line treatment, sulfone (dapsone) 5… |
| 11. Prognosis | Because of its treatment resistance, the prognosis of acquired epidermolysis bullosa is often worse than that of other autoimmune blistering diseases. The classic type responds to treatment… |
| 12. Prevention | Prevention in acquired epidermolysis bullosa focuses on preventing recurrence, protecting the skin, and minimizing scarring. To minimize skin trauma, protective… |
| 13. References | 10 papers in major international journals. |
Acquired epidermolysis bullosa (Acquired Epidermolysis Bullosa, AEB or EBA) is a rare autoimmune blistering disease caused by autoantibodies against type VII collagen (COL7A1), which makes up the anchoring fibrils of the dermal-epidermal junction. It is an entirely different disease from Hereditary Epidermolysis Bullosa, and the term 'acquired' emphasizes onset through an autoimmune mechanism.
This disease originated with the description by the German dermatologist Ernst Hebra in 1895, and was established as an independent disease in 1971 when Roy Roenigk et al. defined clinical and pathologic features distinguishing it from hereditary EBA. In 1984, Leena Lazarova and Paul Yagi et al. partially isolated the AEB autoantigen, and in 1992 John R. Stanley et al. finally identified it as the NC1 domain of type VII collagen. This discovery led to the development of the anti-COL7A1 NC1 ELISA, making serologic diagnosis of AEB possible.
AEB is broadly divided into two clinical types: ① Classic type (non-inflammatory classic EBA): recurrent blisters and scar formation in trauma-prone areas (extensor surfaces such as the backs of the hands, tops of the feet, elbows, and knees). Non-inflammatory, with a negative Nikolsky sign. ② Inflammatory type (inflammatory EBA): an inflammatory pattern resembling bullous pemphigoid or cicatricial pemphigoid. The two forms can convert over time in the same patient. The strong association between AEB and inflammatory bowel disease (especially Crohn's disease) is a notable epidemiological feature.
Acquired epidermolysis bullosa is caused by IgG autoantibodies against the NC1 (non-collagenous 1) domain of type VII collagen (COL7A1), a basement membrane component protein located at the dermal-epidermal junction (DEJ). Type VII collagen is a key structural protein that forms anchoring fibrils beneath the basal layer of the epidermis, mechanically linking the lamina densa of the basement membrane to the dermis. When autoantibodies bind to the NC1 domain, the mechanical function of the anchoring fibrils is impaired and a sublamina densa split occurs.
The subclasses of anti-COL7A1 IgG are mainly IgG1 and IgG4, and there are reports that IgG4 predominates in the classic type and IgG1 in the inflammatory type. In inflammatory AEB, autoantibody-mediated complement activation and neutrophil recruitment are prominent, and elastase, MMPs, and other enzymes secreted by neutrophils degrade the basement membrane, causing inflammatory subepidermal blisters. As mechanisms linking AEB and Crohn's disease, increased immune exposure to COL7A1 epitopes due to intestinal mucosal damage and molecular mimicry with gut bacterial antigens have been hypothesized. Some studies show that HLA-DR2 (DRB1*15:01) is strongly associated as an HLA risk gene.
Acquired epidermolysis bullosa is a complex genetic disease. HLA-DR2 (HLA-DRB1*15:01) is reported as the strongest genetic risk factor, with an odds ratio of about 3~5. There are reports that the incidence of AEB is higher in African American populations than in other races, which may reflect differences in the population frequency of certain HLA alleles. Pathogenic variants in the COL7A1 gene (3p21.31) cause hereditary dystrophic epidermolysis bullosa (Dystrophic EB, DEB) but are unrelated to acquired epidermolysis bullosa. The clinical significance of genetic counseling is limited.
Acquired epidermolysis bullosa is a very rare disease among autoimmune blistering diseases, with an annual incidence estimated at 0.5~2 per 1 million population. The age of onset is broadly distributed, and it can occur at any age from childhood to old age, but adulthood (30s~50s) is most common. In East Asia, including Korea, it is relatively rarer than in the West, but cases have been reported. There are reports of higher incidence in populations of African descent. Inflammatory bowel disease (mainly Crohn's disease) accompanies about 25~30% of AEB patients, suggesting a common immune pathway for the two diseases. Conversely, the risk of AEB in patients with Crohn's disease is higher than in the general population.
The pathophysiology of acquired epidermolysis bullosa is damage to anchoring fibrils and sub-basement membrane cleavage caused by anti-COL7A1 IgG autoantibodies. In the classic (non-inflammatory) type, autoantibodies bind to COL7A1 and weaken the mechanical binding strength of the anchoring fibrils, so that even minor trauma to the skin (friction, pressure) causes epidermal-dermal separation and blister formation. This mechanism is similar to hereditary dystrophic epidermolysis bullosa, in which anchoring fibrils are deficient due to COL7A1 gene variants, producing the same result. In inflammatory AEB, the key mechanisms after autoantibody binding are activation of the complement pathway (C1q, C3b, C5a), recruitment of mast cells and neutrophils, and degradation of basement membrane proteins by neutrophil elastase and MMP-9. This inflammation-mediated mechanism produces a clinical phenotype similar to BP. In Crohn's disease, increased immune exposure of the COL7A1 antigen due to intestinal mucosal damage is presumed to act as a catalyst for gut-skin immune cross-reactivity.
The clinical symptoms of acquired epidermolysis bullosa are broadly divided into the classic and inflammatory types. Classic (non-inflammatory) type: blisters recur in trauma-prone areas (extensor prominences such as the backs of the hands, tops of the feet, finger joints, elbows, knees, and anterior shins), and after healing, white scars (scarring erosions), milia, and hypertrophic scars remain. Blisters occur even with minor provoking trauma, and the Nikolsky sign is negative. Nail loss or dystrophic nails may appear. This form, in which skin fragility is prominent, is clinically very similar to hereditary dystrophic EBA, so differential diagnosis is important. Inflammatory type: a pattern resembling bullous pemphigoid or cicatricial pemphigoid, in which tense blisters arise on generalized erythematous plaques or mucosal involvement (oral, conjunctival, esophageal) appears. Pruritus accompanies, and the Nikolsky sign may be positive. Symptoms of inflammatory bowel disease such as Crohn's disease often accompany or precede it.
The physical signs of classic AEB are recurrent blisters, scars, milia, and dystrophic nail changes on the extensor surfaces. Skin fragility is evident, so erosions occur even after removal of skin tape. In the inflammatory type, tense blisters, urticarial erythema, and mucosal erosions are observed. Characteristic laboratory findings are a positive anti-COL7A1 NC1 ELISA, dermal-side fluorescence on IIF of salt-split skin (distinguished from the epidermal side in bullous pemphigoid), and DIF (linear IgG and C3 along the basement membrane zone; IgA is also possible in the classic type). Increases in serum CRP, ESR, and eosinophils are observed in the inflammatory type. When Crohn's disease accompanies, intestinal symptoms (abdominal pain, diarrhea, bloody stools) accompany.
Screening tests for acquired epidermolysis bullosa are performed in patients who do not respond to treatment for other autoimmune blistering diseases, in patients with recurrent blisters and scars on the extensor surfaces, and when blistering skin lesions develop in patients with Crohn's disease. The anti-COL7A1 NC1 ELISA is the key screening test, with a sensitivity of about 80~85% and a specificity of about 95% or higher. On IIF using salt-split human skin as substrate, dermal-side fluorescence suggests AEB (BP is epidermal-side). Combining these two tests allows differentiation from BP and other basement membrane diseases. Antibody specificity for COL7A1 is confirmed by immunoblot, ELISA, and immunoprecipitation.
Confirmation of acquired epidermolysis bullosa is made by integrating clinical findings, histopathology, DIF, IIF, and ELISA. On histopathology, blister formation below the basement membrane (sublamina densa) is the typical finding. Transmission electron microscopy (TEM) can confirm loss or reduction of anchoring fibrils. On DIF, linear IgG and C3 deposition along the basement membrane zone is observed, and dermal-side fluorescence on DIF or IIF of salt-split skin is the decisive finding. A positive anti-COL7A1 ELISA confirms the diagnosis. Differential diagnoses include hereditary dystrophic EBA (COL7A1 gene variant testing), cicatricial pemphigoid (anti-laminin-332), and BP (anti-BP180). Intestinal examination is needed to evaluate for accompanying Crohn's disease.
Acquired epidermolysis bullosa is more treatment-resistant than other autoimmune blistering diseases. As first-line treatment, sulfone (dapsone) 50~200 mg/day, colchicine, or systemic corticosteroids are used. Steroid monotherapy often has a limited long-term response, so combination with immunosuppressants is needed from the outset. Cyclosporine A has been confirmed in several studies as a particularly effective immunosuppressant in classic AEB. Mycophenolate mofetil and azathioprine are also used for steroid-sparing purposes. High-dose IVIG therapy has been reported to be effective in recurrent and refractory AEB. Rituximab is expected to reduce autoantibodies through B-cell depletion in patients who have failed steroids and immunosuppressants. In patients with accompanying Crohn's disease, there are case reports that treatment of Crohn's disease (anti-TNF agent: infliximab) also helps improve AEB skin lesions.
Because of its treatment resistance, the prognosis of acquired epidermolysis bullosa is often worse than that of other autoimmune blistering diseases. The classic type responds relatively better to treatment, but irreversible skin changes such as scars and milia accumulate. The inflammatory type may show an initial response to treatment, but relapses are frequent. Overall, achieving long-term complete remission is difficult, and the course is chronic and relapsing. When there is conjunctival, laryngeal, or esophageal involvement, scarring complications (blindness, airway stenosis, esophageal stricture) affect quality of life and survival. In patients with accompanying Crohn's disease, control of both diseases is needed, and combined use of anti-TNF agents may contribute to improved prognosis. Disease activity is monitored with regular follow-up testing (anti-COL7A1 ELISA, evaluation of related organs).
Prevention in acquired epidermolysis bullosa focuses on preventing recurrence, protecting the skin, and minimizing scarring. To minimize skin trauma, protective clothing (thick gloves, cushioned insoles), friction-reducing ointments, and acrylic dressing materials are used. Infection prevention during immunosuppressive therapy (vaccination, early wound care) is important. Control of inflammatory bowel disease such as Crohn's disease helps stabilize skin lesions. G6PD deficiency must be checked before using sulfones. Patients with the classic type need lifestyle guidance to avoid physical stimuli such as burns, heat, and strong friction. Regular dermatologic follow-up detects early relapses so that treatment can be resumed.